Cell Therapeutics, Inc. Receives Orphan Drug Designation in Europe to Treat Multiple Myeloma and Myelodysplastic Syndromes With TRISENOX(TM)

Orphan Drug Designation in Europe Provides Ten Years of Market Exclusivity

Upon Approval of Marketing Authorization Application



Apr 04, 2001, 01:00 ET from Cell Therapeutics, Inc.

    SEATTLE, April 4 /PRNewswire/ --
 Cell Therapeutics, Inc.'s (cti) (Nasdaq: CTIC) TRISENOX (arsenic trioxide)
 injection has been granted orphan medicinal product designation for the
 treatment of multiple myeloma and myelodysplastic syndromes by the European
 Commission.
     "We are pleased that the Commission has granted this designation of
 TRISENOX as an orphan medicinal product for these treatments.  Orphan
 designation for medicinal products in Europe provides up to 10 years of market
 exclusivity upon approval of the product for the orphan indication," stated
 James A. Bianco, M.D., President and CEO at cti.  "These two orphan drug
 designations in Europe follow the one we received for TRISENOX to treat acute
 promyelocytic leukemia just last year."
     Orphan designation for TRISENOX in treating multiple myeloma was granted
 to Cell Therapeutics (UK) Ltd. and is granted for treatments that may offer
 significant benefit in patients with serious or life threatening diseases that
 occur in not more than 200,000 patients.
     In February, the Company announced that the EMEA validated the Marketing
 Authorization Application (MAA) it submitted for TRISENOX for the treatment of
 acute promyelocytic leukemia.
     The EMEA represents 15 European Union countries, including France, Italy,
 the United Kingdom, Spain, and Germany.
     cti is committed to developing an integrated portfolio of oncology
 products aimed at making cancer more treatable.
 
     This announcement includes forward-looking statements that involve a
 number of risks and uncertainties, the outcome of which could materially
 and/or adversely affect actual future results.  Specifically, the risks and
 uncertainties that could affect the development of cti's products under
 development include risks associated with preclinical and clinical
 developments in the biopharmaceutical industry in general and of cti's
 products under development in particular including, without limitation, the
 potential failure of all compounds to prove safe and effective for treatment
 of disease, determinations by regulatory, patent and administrative
 governmental authorities, competitive factors, technological developments,
 costs of developing, producing and selling cti's products under development,
 and the risk factors listed or described from time to time in the Company's
 filings with the Securities and Exchange Commission including, without
 limitation, the Company's most recent registrations on Forms 10-K, 8-K, S-3
 and 10-Q.
 
 

SOURCE Cell Therapeutics, Inc.
    SEATTLE, April 4 /PRNewswire/ --
 Cell Therapeutics, Inc.'s (cti) (Nasdaq: CTIC) TRISENOX (arsenic trioxide)
 injection has been granted orphan medicinal product designation for the
 treatment of multiple myeloma and myelodysplastic syndromes by the European
 Commission.
     "We are pleased that the Commission has granted this designation of
 TRISENOX as an orphan medicinal product for these treatments.  Orphan
 designation for medicinal products in Europe provides up to 10 years of market
 exclusivity upon approval of the product for the orphan indication," stated
 James A. Bianco, M.D., President and CEO at cti.  "These two orphan drug
 designations in Europe follow the one we received for TRISENOX to treat acute
 promyelocytic leukemia just last year."
     Orphan designation for TRISENOX in treating multiple myeloma was granted
 to Cell Therapeutics (UK) Ltd. and is granted for treatments that may offer
 significant benefit in patients with serious or life threatening diseases that
 occur in not more than 200,000 patients.
     In February, the Company announced that the EMEA validated the Marketing
 Authorization Application (MAA) it submitted for TRISENOX for the treatment of
 acute promyelocytic leukemia.
     The EMEA represents 15 European Union countries, including France, Italy,
 the United Kingdom, Spain, and Germany.
     cti is committed to developing an integrated portfolio of oncology
 products aimed at making cancer more treatable.
 
     This announcement includes forward-looking statements that involve a
 number of risks and uncertainties, the outcome of which could materially
 and/or adversely affect actual future results.  Specifically, the risks and
 uncertainties that could affect the development of cti's products under
 development include risks associated with preclinical and clinical
 developments in the biopharmaceutical industry in general and of cti's
 products under development in particular including, without limitation, the
 potential failure of all compounds to prove safe and effective for treatment
 of disease, determinations by regulatory, patent and administrative
 governmental authorities, competitive factors, technological developments,
 costs of developing, producing and selling cti's products under development,
 and the risk factors listed or described from time to time in the Company's
 filings with the Securities and Exchange Commission including, without
 limitation, the Company's most recent registrations on Forms 10-K, 8-K, S-3
 and 10-Q.
 
 SOURCE  Cell Therapeutics, Inc.